OA
REGN icon

Oasis Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Oasis Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,440
Closed -$1.11M – 191
2026
Q1 		$1.11M Buy
+1,440
New +$1.1M 0.22% 68

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Oasis Advisors's REGN Position: Q2 2026 in Review

Oasis Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 1,440 shares — an estimated $1.11M sold.

Oasis Advisors first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $1.11M in Q1 2026. 485 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Oasis Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Oasis Advisors sold 1,440 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
  • Oasis Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Oasis Advisors's Regeneron Pharmaceuticals position peaked at $1.11M in Q1 2026.
  • 485 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Oasis Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.